Stratos built a HIPAA-compliant genomic data platform in 12 weeks
Stratos BioSciences, a division of Stratos Defence Group, deployed HIPAA-compliant compute enclaves on Novastraxis, built a high-throughput genomic workflow engine, and accelerated their FDA submission timeline by 5 months.
Stratos BioSciences
Precision Medicine & Genomics
Division of
Stratos Defence Group
Employees
3,200
Headquarters
Cambridge, MA
Industry
Healthcare & Life Sciences
Key Results at a Glance
94%
Reduction in Processing Time
8 weeks
To Full Compliance
200TB
Scalable Processing Capacity
100%
Audit Trail Coverage
5 months
FDA Timeline Acceleration
The Challenge
A precision medicine company racing against clinical trial deadlines
Stratos BioSciences, the precision medicine division of Stratos Defence Group, was developing a breakthrough oncology therapeutic that depended on large-scale genomic analysis. With 3,200 employees and laboratories across 6 sites, the company processed 40 terabytes of sequencing data daily. But their existing cloud infrastructure was failing them at every level: performance, compliance, and data sovereignty.
40TB Daily Data Processing
The genomic sequencing pipeline generated 40 terabytes of raw data daily from next-generation sequencing instruments across 6 laboratory sites. Existing infrastructure could not process this volume without severe queueing and job failures.
72-Hour Processing Bottleneck
End-to-end genomic workflow processing — from raw FASTQ files through alignment, variant calling, and annotation — took 72 hours on existing cloud infrastructure. Clinical decision timelines required results within a single business day.
HIPAA Compliance Gaps
Protected Health Information (PHI) commingled with research data across multiple cloud accounts. Access controls were inconsistent, audit trails were incomplete, and breach notification procedures had not been tested.
FDA 21 CFR Part 11 Requirements
Clinical trial data required compliance with FDA 21 CFR Part 11 for electronic records and electronic signatures. The existing system lacked validated audit trails, access controls, and the tamper-evident logging required for regulatory submissions.
Data Residency Concerns
Patient genomic data processed through a global cloud provider was being routed through international nodes with no guaranteed data residency. Institutional review boards (IRBs) and patient consent agreements required US-only processing.
Clinical Trial Timeline Pressure
A Phase II clinical trial for a precision oncology therapeutic was dependent on genomic analysis of 12,000 patient samples. Processing delays were projected to push the FDA submission timeline back by 8 months, threatening the competitive window.
The Solution
HIPAA-compliant genomic infrastructure built for clinical-grade performance
Novastraxis designed and deployed a purpose-built genomic data platform that met the intersecting requirements of HIPAA, FDA 21 CFR Part 11, institutional review boards, and the throughput demands of next-generation sequencing at clinical scale.
HIPAA-Compliant Compute Enclaves
Deployed dedicated HIPAA-compliant compute enclaves on Novastraxis Core Infrastructure with physical isolation for PHI workloads. All genomic data processing occurs within encrypted enclaves with hardware-rooted attestation and automatic PHI classification.
Explore Core InfrastructureGenomic Workflow Engine on Data Mesh
Built a high-throughput genomic workflow engine on the Novastraxis Data Mesh platform. The pipeline handles FASTQ ingestion, BWA-MEM2 alignment, GATK variant calling, and VEP annotation as federated data products with lineage tracking and reproducibility guarantees.
Discover Data Mesh EngineFDA-Compliant Audit Trail System
Implemented a comprehensive audit trail system meeting FDA 21 CFR Part 11 requirements for electronic records. Every data access, modification, and computation is logged with tamper-evident hashing, electronic signature capture, and validated timestamps.
Sovereign Data Residency Configuration
Configured guaranteed US-only data processing and storage with jurisdictional isolation at the infrastructure layer. All genomic data, intermediate computation artifacts, and clinical trial records are processed exclusively within Novastraxis US regions with cryptographic residency attestation.
The Results
From 72-hour bottleneck to same-day genomic insights
The platform transformation delivered performance improvements that directly accelerated the clinical trial timeline and established a compliance posture ready for FDA scrutiny.
94%
Reduction in Processing Time
Before
72 hours
After
4.5 hours
End-to-end genomic workflow processing dropped from 72 hours to 4.5 hours through parallelized compute enclaves, optimized data pipeline architecture, and GPU-accelerated variant calling. Clinicians now receive actionable genomic insights within a single business day.
8 weeks
To Full Compliance
Before
Non-compliant
After
HIPAA + 21 CFR Part 11
Achieved full HIPAA compliance and FDA 21 CFR Part 11 validation in 8 weeks using pre-configured compliance templates and automated control implementation on Novastraxis. Independent audit confirmed zero control gaps across all applicable requirements.
200TB
Scalable Processing Capacity
Before
40TB/day (at limit)
After
200TB/day capacity
Current daily processing of 40TB runs well within the platform's demonstrated capacity of 200TB per day. Auto-scaling compute enclaves provision additional resources based on sequencing pipeline throughput, ensuring the platform grows with research demands.
100%
Audit Trail Coverage
Before
Partial logging
After
Complete coverage
Every data access, transformation, and computation across the entire genomic pipeline is logged with tamper-evident audit trails. Clinical trial data integrity is maintained with cryptographic hash chains that FDA inspectors can independently verify.
5 months
FDA Timeline Acceleration
Before
8-month delay projected
After
5 months ahead of schedule
The Phase II clinical trial genomic analysis was completed 5 months ahead of the revised projections. Faster processing enabled Stratos to submit the Investigational New Drug (IND) application to the FDA within the original competitive window.
Implementation Timeline
12 weeks from assessment to clinical-grade production
The accelerated timeline was critical given the Phase II clinical trial schedule. Three tightly coordinated phases delivered compliance, performance, and scale in rapid succession.
Phase 1
Assessment & Compliance Architecture
Weeks 1 - 3
- Comprehensive data classification audit of all genomic, clinical, and research datasets across 6 laboratory sites
- HIPAA gap assessment and remediation roadmap with PHI data flow mapping and risk analysis
- FDA 21 CFR Part 11 requirements analysis for electronic records and signature workflows in the genomic pipeline
- Compute enclave architecture design with PHI isolation, encryption requirements, and access control policies
- Data residency configuration design for guaranteed US-only processing with cryptographic attestation
- IRB and patient consent review to validate data handling procedures against institutional requirements
Phase 2
Platform Build & Compliance Validation
Weeks 4 - 8
- HIPAA-compliant compute enclave deployment with hardware-rooted attestation and automatic PHI detection
- Genomic workflow engine build-out on Data Mesh: FASTQ ingestion, alignment, variant calling, and annotation pipelines
- FDA 21 CFR Part 11 audit trail system implementation with tamper-evident hashing and electronic signature capture
- Sovereign data residency activation with US-only processing guarantees and jurisdiction isolation
- Performance benchmarking: throughput testing with 40TB daily data volumes across parallelized compute nodes
- Independent HIPAA compliance audit by third-party assessor with zero findings
Phase 3
Clinical Trial Integration & Scale
Weeks 9 - 12
- Integration of Phase II clinical trial sample processing pipeline with 12,000-patient sample queue
- GPU-accelerated variant calling optimization reducing per-sample processing from 6.2 hours to 22 minutes
- Auto-scaling configuration to handle peak sequencing throughput from all 6 laboratory sites simultaneously
- FDA pre-submission meeting preparation with validated audit trail documentation package
- Operational runbook creation and knowledge transfer to Stratos bioinformatics engineering team
- Continuous compliance monitoring activation with real-time dashboards for HIPAA and 21 CFR Part 11 controls
“In precision medicine, time is not a metaphor — it is the difference between a patient receiving a targeted therapy and receiving a generic one. Novastraxis gave us the infrastructure to process genomic data at clinical speed with FDA-grade auditability. Going from 72 hours to 4.5 hours per workflow did not just accelerate our trial — it changed what we believe is computationally possible in genomics.”
Dr. Priya Ramanathan
Vice President of Data Science, Stratos BioSciences
Related Resources
Your Turn
Building a compliant life sciences data platform?
Our healthcare and life sciences team has deep expertise in HIPAA, FDA 21 CFR Part 11, and genomic data infrastructure. Let us design a platform that meets your regulatory and performance requirements.
Request Enterprise Demo